Related Experiment Video
Updated: Jun 18, 2025
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Adverse Drug Reactions of Multiple Sclerosis Disease-modifying Drugs
Maryam Salehbayat1, Roya Abolfazli2, Niayesh Mohebbi3,4
1School of Pharmacy, International Campus, Tehran University of Medical Sciences, Tehran, Iran.
Introduction:
High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study.
Methods:
ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated.
Results:
A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious.
Conclusion:
The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients' adherence to treatment.
Highlights:
Adverse drug reactions (ADRs) are common in MS patients using disease modifying therapies.Such ADRs are more common in women than men.Various brand names of biosimilar disease-modifying therapy (DMT)s may have a different ADR profile.
Plain Language Summary:
Multiple sclerosis (MS) is a condition that can be managed by using disease modifying medications. Such medication could trigger an adverse reaction in the patients., affecting their commitment to the treatment. By identifying these adverse reactions and educating the MS patients about these reactions and how the adverse effects can be managed, healthcare providers can improve the treatment process. This study recorded the adverse drug reactions in 250 MS patients who were receiving the medication for at least three months. Most of the patients (76.4%) experienced some kind of adverse reaction. A bigger proportion of women experienced adverse reactions than men. About 84% of these reactions occurred within the first 3 hours of receiving the medication. Depending on the medication's brand name, the rate of adverse drug reactions were different in some cases. The results of this study point out the fact that experiencing adverse drug reactions is common in MS patients and these experiences could be different for each medication with a different brand name. Therefore, it is important for the healthcare providers to inform the patients about such reactions and the patients should seek all the information they need to manage these adverse effects by consulting their physician.
Insights
Adverse drug reactions (ADRs) are frequent in multiple sclerosis (MS) patients using disease-modifying therapies (DMTs). Understanding these ADRs is crucial for improving treatment adherence and patient outcomes in MS care.
Area of Science:
- Neurology
- Pharmacology
- Clinical Research
Background:
- Adverse drug reactions (ADRs) pose a significant challenge to the effective treatment of multiple sclerosis (MS).
- Disease-modifying therapies (DMTs) are essential for managing MS but can be associated with various ADRs.
- High ADR frequency can negatively impact patient adherence to crucial MS treatments.
Purpose of the Study:
- To investigate the nature and frequency of ADRs experienced by patients undergoing MS treatment.
- To assess the characteristics of ADRs, including preventability and severity.
- To identify potential differences in ADR profiles among various DMT brand names.
Main Methods:
- An observational, cross-sectional study design was employed.
- Data were collected from outpatients receiving at least one DMT for MS within the preceding three months.
- A total of 250 MS patients were included in the analysis.
Main Results:
- A substantial number of ADRs (484) were identified across the patient cohort.
- The overall preventability rate of ADRs was 5.9%, with 0.61% classified as serious.
- ADRs were more prevalent in women than men, and timing of onset often occurred within 3 hours of medication intake.
Conclusions:
- The high incidence of ADRs underscores the need for strategic interventions to enhance patient adherence to MS therapies.
- Educating patients about potential ADRs and their management is vital for optimizing treatment outcomes.
- Variations in ADR profiles across different DMT brand names warrant further investigation and personalized patient counseling.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Skeletal Muscle Relaxants: Adverse Effects
Unlike...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Drug Therapy
Antianxiety Medications
01:30Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...